lansoprazole/amoxicillin/clarithromycin (Rx)

Brand and Other Names:Prevpac

Dosing & Uses


Dosage Forms & Strengths


capsule/capsule/tablet prepack

  • 30mg/500mg/500mg
  • amoxicillin component consists of 2 capsules (500 mg/capsule)

Duodenal Ulcer

Eradication of H. pylori to reduce risk of duodenal ulcer recurrence

Lansoprazole 30 mg, amoxicillin 1 g, clarithromycin 500 mg administered together PO twice daily (morning and evening) for 10 or 14 days

Each dose of this combination therapy contains 4 pills: 1 capsule lansoprazole 30 mg, 2 capsules amoxicillin 500 mg, and 1 tablet clarithromycin 500 mg

Prevpac is clearly labeled for administration of 1 dose (30 mg/1 g/500 mg) PO twice daily

Dosage Modifications

Severe renal impairment (CrCl <30 mL/min): Do not use

Hepatic impairment: Not dosage adjustment required

Safety and efficacy not established


Adverse Effects



  • GI effects, general (13%)



  • Headache (6%)
  • Rash (children 3%)
  • Abdominal pain (adults 2%, children 3%)
  • Abnormal taste (adults 3-7%)
  • Diarrhea (3-6%)
  • Dyspepsia (2%)
  • Heartburn (adults 2%)
  • GI intolerance (oral-dose related)
  • Nausea (adults 3-6%)
  • Vomiting (adults 1%; children 6%)
  • Decreased WBC, elevated BUN (4%), elevated PT (1%)


  • Fatigue (< 3%)
  • Headache (2.5-4.7%)
  • Abdominal pain (1.8%)
  • Diarrhea (8%)
  • Nausea (3.7%)



  • QT prolongation
  • Anxiety, dizziness, hallucinations, manic behavior, neuromuscular blockade, psychosis, seizures
  • Anorexia, glossitis, pancreatitis
  • AST increased, bilirubin increased, elevated LFTs, hepatic dysfunction, hepatitis, increased alkaline phosphate, jaundice
  • Hypoglycemia, leukopenia, neutropenia, thrombocytopenia
  • Increased serum creatinine
  • Dyspnea
  • Anaphylaxis, C Diff colitis, Stevens-Johnson syndrome

Frequency Not Defined


  • Headache
  • Rash
  • Diarrhea, nausea, vomiting
  • Anemia
  • AST/ALT elevation
  • Acute exanthematous pustulosis
  • Exfoliative dermatitis
  • Seizure
  • Insomnia
  • Hemorrhagic colitis
  • Toxic epidermal necrolysis
  • Urticaria
  • Stevens-Johnson syndrome
  • Anaphylaxis
  • Candidiasis (mucocutaneous), pseudomembranous colitis, serum sickness


  • Torsade de pointes (rare)
  • Allergic reactions: urticaria & skin eruptions, leukocytoclastic vasculitis, toxic epidermal necrolysis, pruritus, rash
  • Transient CNS effects: psychosis, anxiety, behavioral changes, confusional states, depersonalization, disorientation, hallucinations, insomnia, nightmares, tinnitus, tremor, and vertigo
  • Hepatic failure
  • Stomatitis
  • Acute renal failure
  • Reversible hearing loss (hypoacusis)


  • Fundic gland polyps




  • Hypersensitivity to lansoprazole or other proton pump inhibitors
  • Coadministration with rilpivirine containing products


  • History of severe hypersensitivity reactions (eg, anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or other beta-lactam antibiotics (eg, penicillins and cephalosporins)
  • Infectious mononucleosis (relative)


  • Documented hypersensitivity
  • Clarithromycin/ranitidine bicitrate contraindicated in: severe renal impairment (CrCl<25 mL/min); history of acute porphyria
  • QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes
  • Concomitant administration with HMG-CoA reductase inhibitors
  • History of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin
  • Coadministration with colchicine in patients with renal or hepatic impairment


Consider possibility of superinfections with fungal or bacterial pathogens during therapy; if superinfections occur, discontinue therapy and institute appropriate therapy; prescribing therapy either in absence of proven or strongly suspected bacterial infection is unlikely to provide benefit to patient and increases risk of development of drug-resistant bacteria


  • Liver disease may require dosage reduction
  • Published observational studies suggest that proton pump inhibitor (PPI) therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine; particularly with prolonged (>1 yr), high-dose therapy
  • Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) reported with PPIs; avoid using for longer than medically indicated; discontinue if signs or symptoms consistent with CLE or SLE are observed and refer patient to specialist
  • Hypomagnesemia may occur with prolonged use (ie, >1 year); adverse effects may result and include tetany, arrhythmias, or seizures; in 25% of cases reviewed, magnesium supplementation alone did not improve low serum magnesium levels and the PPI had to be discontinued
  • PPIs possibly associated with increased incidence of Clostridium difficile-associated diarrhea (CDAD); consider diagnosis of CDAD for patients taking PPIs with diarrhea that does not improve
  • Symptomatic response to therapy with lansoprazole does not preclude the presence of gastric malignancy; consider additional follow-up and diagnostic testing in adult patients who have a suboptimal response or an early symptomatic relapse after completing treatment with a PPI; in older patients, also consider endoscopy
  • PPIs may elevate and prolong methotrexate or its metabolite serum levels, possibly leading to toxicity
  • PPI therapy is associated with increased risk of fundic gland polyp; risk increases with long-term use >1 year; patient may be asymptomatic; problem usually identified incidentally on endoscopy; use shortest duration of therapy appropriate to condition being treated
  • Acute interstitial nephritis (AIN) observed in patients taking proton pump inhibitors (PPIs) including lansoprazole; acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction; discontinue lansoprazole if AIN develops


  • Allergy to cephalosporins, carbapenems
  • Endocarditis prophylaxis: use only for high risk pts, per recent AHA Guidelines
  • High doses may cause false urine glucose test by some methods


  • Caution in severe renal or hepatic impairment; in presence of severe renal impairment with or without coexisting hepatic impairment, decreased dosage or prolonged dosing intervals of clarithromycin may be appropriate
  • Do not refrigerate oral solution
  • Endocarditis prophylaxis: use only for high risk patients, per recent AHA Guidelines
  • Drug has been associated with prolongation of QT interval and infrequent cases of arrhythmia; cases of torsades de pointes spontaneously reported during postmarketing surveillance; fatalities reported; avoid therapy in patients with ongoing proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia and in patients receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents; elderly patients may be more susceptible to drug-associated effects on the QT interval
  • Concomitant use of clarithromycin and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia
  • There is a risk of serious hemorrhage and significant elevations in INR and prothrombin time when clarithromycin is co-administered with warfarin; monitor INR and prothrombin times
  • Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, reported with drug; hepatic dysfunction may be severe and usually reversible; in some instances, hepatic failure with fatal outcome reported and generally associated with serious underlying diseases and/or concomitant medications; symptoms of hepatitis can include anorexia, jaundice, dark urine, pruritus, or tender abdomen; discontinue clarithromycin immediately if signs and symptoms of hepatitis occur
  • Hypersensitivity reactions
    • Individuals with a history of penicillin hypersensitivity who have experienced severe reactions when treated with cephalosporins reported
    • Before initiating therapy perform careful inquiry regarding previous hypersensitivity reactions to penicillins, cephalosporins, or other allergens
    • In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), and Henoch-Schonlein purpura discontinue therapy immediately and urgently initiate appropriate treatment

Drug interaction overview

Serious adverse reactions reported with clarithromycin concomitantly with CYP3A4 substrates; these include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; hypoglycemia with disopyramide, and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (eg, verapamil, amlodipine, diltiazem, nifedipine); most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older; clarithromycin should be used with caution when administered concurrently with medications that induce cytochrome CYP3A4 enzyme


Pregnancy & Lactation



  • No adequate and well-controlled studies in pregnant women; do not use clarithromycin in pregnant women except in circumstances in which no alternative therapy is appropriate
  • If pregnancy occurs while taking clarithromycin, inform patient of paotential hazard to fetus; drug has demonstrated adverse effects of prengnacy outcome and/or embryofetal development in monkeys, rats, mice, and rabbits at doses that produced plasma levels 2 to 17 times serum levels achieved in humans treated at maximum recommended human doses


  • Available data from published observational studies overall do not indicate an association of adverse pregnancy outcomes with lansoprazole treatment; estimated background risk of major birth defects and miscarriage for the indicated populations are unknown
  • Available data from published observational studies failed to demonstrate an association of adverse pregnancy-related outcomes and lansoprazole use; methodological limitations of these observational studies cannot definitely establish or exclude any drug-associated risk during pregnancy
  • No adverse effects on embryo-fetal development occurred in studies performed in pregnant rats at oral lansoprazole doses up to 150 mg/kg/day (40 times the recommended human dose [30 mg/day] based on body surface area) administered during organogenesis and pregnant rabbits at oral lansoprazole doses up to 0 mg/kg/day (16 times the recommended human dose based on body surface area) administered during organogenesis


  • Adverse events not observed in animal reproduction studies; maternal use has not resulted in increased risk of adverse fetal effects; however, possible association with cleft lip with cleft palate observed in some studies; more data needed


Caution should be exercised when clarithromycin is administered to nursing women; the development and health benefits of human milk feeding should be considered along with the mother’s clinical need for clarithromycin and any potential adverse effects on human milk- fed child from the drug or from underlying maternal condition

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.



Mechanism of Action

Lamsoprazole: Proton pump inhibitor; binds to H+/K+-exchanging ATPase (proton pump) in gastric parietal cells resulting in blocking acid secretion

Amoxicillin: Inhibits bacterial cell wall synthesis by binding to one or more penicillin binding proteins that in turn inhibit the final transpeptidation step of peptoglycan synthesis in cell wall biosynthesis

Clarithromycin: Inhibits protein synthesis by binding to 50S ribosomal subunit causing antibacterial activity


Half-Life: 0.9-1.5 hr

Bioavailability: 81-91% (empty stomach); 50-70% (30 minutes after food)

Clearance Total Body: 0.7 L/hr/kg

Onset of action: 1-3 hr (gastric acid suppression)

Renal: 517 mL/min

Metabolism: Gastric parietal cells: acidic pH converts lansoprazole to its active sulfenamide metabolites

Liver: by hepatic CYP2C19; slow metabolizers are deficient in CPY2C19 enzyme & can have plasma conc can increase 5 times or higher

Metabolites Active: cyclic sulfenamide & disulfide metaboliteInactive: 5-hydroxy-lansoprazole, sulfide metabolite, omeprazole sulfone, sulfone metabolite, hydroxysulfide metabolite, hydroxysulfone metabolite

Excretion: Feces (bile): 77%

Urine: 14-25%

Peak Plasma Time: 1.5-3 hr

Protein Bound: 97-99%

Vd: 14-18 L

Dialyzable: No

Enzymes inhibited: CYP2C19


Half-Life: 3.7 hr (neonates, full term); 1-2 hr (infants and children); 0.7-1.4 hr (adults); 7-21 hr (CrCl < 10 mL/min in adults)

Absorption: 74-92%

Distribution: most body fluids and bone, CSF<1%

Peak Plasma Time: 2hr (capsule); 3.1 hr (extended release tablet); 1 hr (suspension)

Protein Bound: 17-20%

Metabolism: Partially hepatic

Excretion: Urine


Half-Life: 3-7 hr

Peak Plasma Time: 2-3 hr (immediate release); 5-8 hr (extended release)

Absorption: Highly stable in presence of gastric acid (unlike erythromycin); food delays but does not affect extent of absorption

Distribution: Widely into most body tissues except CNS

Protein binding: 42-70%

Metabolism: partially hepatic (P450 enzyme CYP3A4); converted to 14-OH clarithromycin (active metabolite)

Renal Clearance: approximates normal GFR

Excretion: primarily urine



Oral Administration

Contains enteric coated granules (acid labile); do not chew or crush



No images available for this drug.

Patient Handout

A Patient Handout is not currently available for this monograph.


FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient



The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient



The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.